0.4622
price down icon12.54%   -0.0663
after-market Dopo l'orario di chiusura: .45 -0.0122 -2.64%
loading
Precedente Chiudi:
$0.5285
Aprire:
$0.4715
Volume 24 ore:
2.58M
Relative Volume:
0.39
Capitalizzazione di mercato:
$321.81K
Reddito:
-
Utile/perdita netta:
$-14.93M
Rapporto P/E:
-0.00174
EPS:
-266.137
Flusso di cassa netto:
$-15.87M
1 W Prestazione:
-11.12%
1M Prestazione:
-75.93%
6M Prestazione:
-97.72%
1 anno Prestazione:
-97.85%
Intervallo 1D:
Value
$0.46
$0.52
Intervallo di 1 settimana:
Value
$0.4263
$0.67
Portata 52W:
Value
$0.4263
$66.33

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name
Nome
Transcode Therapeutics Inc
Name
Telefono
857-301-6857
Name
Indirizzo
6 LIBERTY SQUARE, BOSTON
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
RNAZ's Discussions on Twitter

Confronta RNAZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNAZ
Transcode Therapeutics Inc
0.4622 321.81K 0 -14.93M -15.87M -266.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie

pulisher
Apr 02, 2025

TransCode Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com

Apr 02, 2025
pulisher
Mar 31, 2025

TransCode Therapeutics Delays Annual Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Emerging Tech QuartetPRSO, LXRX, PRTG, RNAZDrive - openPR.com

Mar 28, 2025
pulisher
Mar 28, 2025

Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

(RNAZ) Investment Analysis - news.stocktradersdaily.com

Mar 28, 2025
pulisher
Mar 27, 2025

Small Cap Stocks To Follow TodayMarch 23rd - MarketBeat

Mar 27, 2025
pulisher
Mar 27, 2025

TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138 - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Cancer Drug Trial Hits Major Milestone: Zero Toxicity as Doses Increase 50% - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

TransCode's $10M Capital Raise Powers Critical Cancer Drug Clinical Trials - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Transcode Therapeutics stock hits 52-week low at $0.64 By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

TransCode Therapeutics Announces $10M Stock And Warrant Offering - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Sector Update: Health Care Stocks Rise Late Afternoon - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Transcode Therapeutics stock hits 52-week low at $0.64 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Transcode to sell 10.25M shares at 98c per share in registered direct offering - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

TransCode Therapeutics Starts $10 Million Direct Offering of Stock, Warrants -March 24, 2025 at 03:42 am EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - Stock Titan

Mar 23, 2025
pulisher
Mar 23, 2025

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire

Mar 23, 2025
pulisher
Mar 22, 2025

Small Cap Stocks To ResearchMarch 21st - MarketBeat

Mar 22, 2025
pulisher
Mar 21, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 21, 2025
pulisher
Mar 17, 2025

(RNAZ) Long Term Investment Analysis - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 15, 2025

HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

RNAZ stock touches 52-week low at $0.69 amid sharp annual decline - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138 - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Transcode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approved - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - Longview News-Journal

Mar 13, 2025
pulisher
Mar 12, 2025

Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews

Mar 12, 2025
pulisher
Mar 10, 2025

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care - Cancer Network

Mar 10, 2025
pulisher
Mar 07, 2025

Transcode Therapeutics stock hits 52-week low at $1.7 By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

Transcode Therapeutics stock hits 52-week low at $1.7 - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews

Mar 06, 2025
pulisher
Mar 03, 2025

The Significance of Moving Averages in TransCode Therapeutics Inc Inc. (RNAZ) Price Performance - The InvestChronicle

Mar 03, 2025
pulisher
Feb 27, 2025

Transcode Therapeutics stock hits 52-week low at $2.62 By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

Transcode Therapeutics stock hits 52-week low at $2.62 - Investing.com

Feb 27, 2025
pulisher
Feb 25, 2025

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com UK

Feb 25, 2025
pulisher
Feb 25, 2025

TransCode Therapeutics, Inc. Announces Results of Special Meeting - Yahoo Finance

Feb 25, 2025

Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):